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The first compound reaching the market following the
approval of the official offices is referred to as first-in-
class or breakthrough drug. These compounds consti-
tute a new class of drugs meaning that they introduce a
novel mode of action (MoA) or provide a significant
improvement over the standard therapy, if not enables a
therapy, in terms of efficacy and safety. A follow-on (or
me-too) drug is, in the common understanding, a che-
mical entity which has structural similarity or has the
same pharmacological MoA as the first-in-class drug.
The approach of follow-on drugs is controversially dis-
cussed in the literature [1-3].
Based on the GVKBIO Medicinal Chemistry and Tar-
get Class databases (which capture explicit relationships
between published documents, compounds, assay results
and targets), we investigated the occurrence of drug dis-
covery follow-on activities as captured by the pharma-
ceutical patent space [4]. To do so, we abstracted from
the GVKBIO databases 11,827 patents which are linked
to a GPCR target with a defined Entrez Gene ID (as
November 2010). In a next step, we removed all peptide
structures because of the size and the similarity of their
backbone. Subsequently, we kept all 10,253 patents
belonging to the TOP 100 companies in terms of num-
ber of patents published. The set was consolidated by
merging patents for known mergers and acquisitions
until 2008. All possible patent combinations were cre-
ated if they share an official gene name and are pub-
lished by different companies within a 6-year interval.
Similarity descriptors and scores could be generated for
1,570,381 out of a total of 1,608,368 pairs (97.6%) [5].
As expected, the pharmaceutical research is highly
competitive and dynamic. This is supported by the fact
that most of the follow-on patents are published within
the first two years with a high number of patent pairs
published in the same year. Around 4800 (47%) patents
included in our analysis are linked to follow-on activities
with only small differences between the companies.
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